Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R2 in Follicular Lymphoma
NCT03715309Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Nov 2018
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in follicular lymphoma (FL), sponsored by Ruijin Hospital. Primary endpoint: Complete Response at 12 weeks. Status: unknown.
02
Drugs
lenalidomide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03715309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03715309.